English
SlovenčinaDepartment of tumor immunology
Research Topic
The Department of Tumor Immunology is devoted to the study of mechanisms of development and progression of hematological B-cell malignancies, especially multiple myeloma and lymphomas, in order to develop targeted therapy for the elimination of cancer.
Our current research focus around multiple aspects of translational hematological research:
- Study of clonal heterogeneity during development and progression of multiple myeloma.
- Large-scale genomic and proteomic profiling in Waldenström Macroglobulinemia (WM) and multiple myeloma.
- Mechanisms of evolution from precursor premalignant stages (MGUS, smoldering MM and smoldering WM) to active malignant disease.
- Role of the tumor microenvironment in regulation of clonal selection and progression of multiple myeloma.
- Tumor-stromal-immune cell interactions in the tumorsuppressive niche of the tumor microenvironment during development and progression of tumor.
- Preparation of the metastatic niche for tumor colonization.
- Role of the tumor microenvironment in regulation of drug resistance.
- Role of circulating tumor cells and mechanisms of cell dissemination (metastasis regulation) in progression of B-cell neoplasms.
- Role of exosomes in cancer progression.
- Use of nanoparticles in the treatment of cancer.
- Effect of chemo- and/or immuno-therapies on intraclonal selection in hematological malignancies.
- Validation and determination of novel chemo- and immunotherapeutic strategies.
Research Team
Head of Department of Tumor Immunology, Cancer Research Institute Biomedical Research Center SAS, Bratislava, SK
Head of Cytoanalytics Laboratory, Biomedical Research Center SAS, Bratislava, SK
Assistant Professor, Department of Tumor Immunology, Cancer Research Institute Biomedical Research Center SAS, Bratislava, SK
Education
Hematology (research fellow in multiple myeloma 2007-2016), Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Oncology (PhD., 2005), Laboratory of Tumor Immunology, Cancer Research Institute Biomedical Research Center SAS, Bratislava, SK
Biochemistry (RNDr., 2001), Faculty of Natural Sciences, Comenius University, Bratislava, SK
Chemistry – Biochemistry (M.S., 1999), Faculty of Natural Sciences, Comenius University, Bratislava, SK
Honors and Grants
Marie Currie Reintegration Award 2015, EU
Multiple Myeloma Research Foundation Research Fellow Award 2012, USA
Junior Chamber International-Slovakia ‘’The Outstanding Young Person’’ award 2007, SK
“Stefan Schwarz award” of Slovak Academy of Sciences for excellent PhD students 2005, SK
Slovak National award “Young Researcher 2005”, SK
Marie Currie Fellowship Award 2002, UK
Fellowships
PhD visiting fellowship 2000-2001, Department of Gynecology and Obstetrics, Vienna General Hospital, Vienna, AU
PhD visiting fellowship 2001-2002, Clinic of Hematology and Blood transfusion LFUK, Bratislava, SK
Marie Curie Training Site Fellowship 2002-2003, Institute of Food Research, Norwich, UK
research fellow 2007-2016, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Contact info:
Cancer Research Institute,
Biomedical Research Center SAS
Blok A, room# 5.29
Dubravská cesta 9
Bratislava 841 05, Slovakia
E-mail: jana.jakubikova@savba.sk; jana.jakubikova@yahoo.com
Tel: +421 2 3229 5158
ORCID 0000-0003-2593-569X
Associate Professor positions:
RNDr. Jan Sedlak, DrSc., Vice Head of Department
Assistant Professor positions:
RNDr. Danka Cholujova, PhD.
Research fellow/ postdoctoral fellow:
Hana Majerova, PhD.
job vacancy
Research Technician
Mgr. Anna Matisova
job vacancy
PhD students:
Mgr. Zuzana Valuskova
Mgr. Patricia Beblava
International research grants:
Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy (ERA-NET: Aligning national/regional translational cancer research programmes and activities TRANSCAN-2 collaborative EU; 2016-2019, J. Jakubikova (coordinator&PI))
Clonal architecture in development of MM and therapy induced intra-clonal heterogeneity in MM progression (Marie Curie Reintegration grant EU; 2015-2018, J. Jakubikova (PI))
National research grants:
Bacterial Lon protease as an emerging tool for multiple myeloma
treatment (APVV; 2022-2026, J. Jakubikova (co-PI))
Cancer immunoediting in multiple myeloma: immune checkpoints and clinical significance (APVV; 20210-2025, J. Jakubikova (PI))
Anti-myeloma activity by composite nanomaterials and its mechanism in vitro and in vivo (VEGA; 2020-2022, J. Jakubikova (PI))
Assessment of immune checkpoints in B cell malignancies (VEGA; 2020-2022, D. Cholujova (PI))
Preparation of new antibiotics and antitumor agents by manipulations of secondary metabolite genes and synthetic biology methods (APVV; 2020-2024, J. Jakubikova (co-PI))
Development of novel diagnostic and predictive high-dimensional immunophenotyping tool for hematological malignancies (Ministry of Health grant 2019/14-BMCSAV-9; 2019-2022, J. Jakubikova (PI))
Harnessing the immunological mechanisms in various subtypes of B cell lymphoma (APVV; 2020-2024, D. Cholujova (PI))
Tumor heterogeneity in multiple myeloma: evolution and clinical significance (APVV; 2017-2021, J. Jakubikova (PI))
Mechanism of anti-tumor activity of realgar nanoparticles and its synergism with anti-myeloma agents (VEGA; 2017-2019, J. Jakubikova J (PI))
The impact of tumor microenvironment and therapy on subclonal diversity in MM and WM (VEGA; 2017-2019, D. Cholujová D (PI))
Prognostic biomarker for colorectal carcinoma based on miRNA analysis and characterization of selected proteins in the circadian context (APVV, 2015-2019, J. Sedlak J (PI))
SELECTED PUBLICATIONS
Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. –2017-BR J HAEMATOL-Oct 19. doi: 10.1111/bjh.14974. PMID: 29048129
Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, Joo J, Kong SY, Szalat RE, Richardson PG, Munshi NC, Dorfman DM, Anderson KC. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. –2016-ONCOTARGET- VOL7(47):77326-77341 PMID:27764795
Pastorek M, Simko V, Takacova M, Barathova M, Bartosova M, Hunakova L, Sedlakova O, Hudecova S, Krizanova O, Dequiedt F, Pastorekova S, Sedlak J. Sulforaphane reduces molecular response to hypoxia in ovarian tumor cells independently of their resistance to chemotherapy.-2015- INT J ONCOL- VOL47 (1): 51-60. PMID: 25955133
https://www.spandidos-publications.com/ijo/47/1/51
Zduriencikova M, Gronesova P, Cholujova D, Sedlak J: Potential biomarkers of exosomal cargo in endocrine signaling -2015-ENDOCR REGUL- VOL49(3):141-50. PMID: 26238497
https://www.ncbi.nlm.nih.gov/pubmed/26238497
Hunakova L, Gronesova P, Horvathova E, Chalupa I, Cholujova D, Duraj J, Sedlak J. Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane.-2014- TOXICOL LETT, VOL230 (3): 479-486. PMID: 25159039
http://www.sciencedirect.com/science/article/pii/S0378427414013083?via%3Dihub
Cholujova D, Jakubikova J, Czako B, Martisova M, Hunakova L, Duraj J, Mistrik M, Sedlak J: MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients-2013-CANCER IMMUNOL IMMUNOTHER- VOL62(3):437-45. PMID: 22941038
https://link.springer.com/article/10.1007%2Fs00262-012-1344-z
Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS: Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications-2011-BLOOD- VOL117(17):4409-19. PMID: 21321360
http://www.bloodjournal.org/content/117/17/4409.long?sso-checked=true
Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS: Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma-2011-HAEMATOLOGICA- VOL96(8):1170-9. PMID: 21712538
http://www.haematologica.org/content/96/8/1170.long
